These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27347117)

  • 1. A comparison of four methods for detecting
    Matsunaga M; Kaneta T; Miwa K; Ichikawa W; Fujita KI; Nagashima F; Furuse J; Kage M; Akagi Y; Sasaki Y
    Oncol Lett; 2016 Jul; 12(1):150-156. PubMed ID: 27347117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Performance of a novel KRAS mutation assay for formalin-fixed paraffin embedded tissues of colorectal cancer.
    Sakai K; Yoneshige A; Ito A; Ueda Y; Kondo S; Nobumasa H; Fujita Y; Togashi Y; Terashima M; De Velasco MA; Tomida S; Nishio K
    Springerplus; 2015; 4(1):7. PubMed ID: 25674493
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [High-throughput screening method of KRAS mutations at codons 12 and 13 in formalin-fixed paraffin-embedded tissue specimens of metastatic colorectal cancer].
    Fukushima Y; Yanaka S; Murakami K; Abe Y; Koshizaka T; Hara H; Samejima C; Kishi Y; Kaneda M; Yoshino T
    Gan To Kagaku Ryoho; 2011 Nov; 38(11):1825-35. PubMed ID: 22083191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validation of targeted next-generation sequencing for RAS mutation detection in FFPE colorectal cancer tissues: comparison with Sanger sequencing and ARMS-Scorpion real-time PCR.
    Gao J; Wu H; Wang L; Zhang H; Duan H; Lu J; Liang Z
    BMJ Open; 2016 Jan; 6(1):e009532. PubMed ID: 26747035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 454 next generation-sequencing outperforms allele-specific PCR, Sanger sequencing, and pyrosequencing for routine KRAS mutation analysis of formalin-fixed, paraffin-embedded samples.
    Altimari A; de Biase D; De Maglio G; Gruppioni E; Capizzi E; Degiovanni A; D'Errico A; Pession A; Pizzolitto S; Fiorentino M; Tallini G
    Onco Targets Ther; 2013; 6():1057-64. PubMed ID: 23950653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Biased discordance of KRAS mutation detection in archived colorectal cancer specimens between the ARMS-Scorpion method and direct sequencing.
    Bando H; Tsuchihara K; Yoshino T; Kojima M; Ogasawara N; Fukushima H; Ochiai A; Ohtsu A; Esumi H
    Jpn J Clin Oncol; 2011 Feb; 41(2):239-44. PubMed ID: 21113056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. KRAS mutations in patients with colorectal cancer as detected by high-resolution melting analysis and direct sequencing.
    Akiyoshi K; Yamada Y; Honma Y; Iwasa S; Kato K; Hamaguchi T; Shimada Y; Taniguchi H; Furuta K
    Anticancer Res; 2013 May; 33(5):2129-34. PubMed ID: 23645765
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Analysis of the correlation with KRAS gene mutation status and the benefit of cetuximab plus irinotecan as third- line chemotherapy for the Treatment of unresectable metastatic colorectal cancer].
    Asai H; Shinozaki E; Nozaki A; Watanabe T; Suenaga M; Matuzaka S; Chin K; Mizunuma N; Yasukawa M; Hatake K
    Gan To Kagaku Ryoho; 2011 Aug; 38(8):1285-91. PubMed ID: 21829065
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Droplet digital PCR revealed high concordance between primary tumors and lymph node metastases in multiplex screening of KRAS mutations in colorectal cancer.
    Vanova B; Kalman M; Jasek K; Kasubova I; Burjanivova T; Farkasova A; Kruzliak P; Busselberg D; Plank L; Lasabova Z
    Clin Exp Med; 2019 May; 19(2):219-224. PubMed ID: 30661213
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
    Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
    Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A rational two-step approach to KRAS mutation testing in colorectal cancer using high resolution melting analysis and pyrosequencing.
    Mack E; Stabla K; Riera-Knorrenschild J; Moll R; Neubauer A; Brendel C
    BMC Cancer; 2016 Aug; 16():585. PubMed ID: 27485514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. KRAS gene mutation in a series of unselected colorectal carcinoma patients with prognostic morphological correlations: a pyrosequencing method improved by nested PCR.
    de Macêdo MP; de Melo FM; Lisboa BC; Andrade LD; de Souza Begnami MD; Junior SA; Ribeiro HS; Soares FA; Carraro DM; da Cunha IW
    Exp Mol Pathol; 2015 Jun; 98(3):563-7. PubMed ID: 25835782
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Concordance in KRAS and BRAF mutations in endoscopic biopsy samples and resection specimens of colorectal adenocarcinoma.
    Krol LC; 't Hart NA; Methorst N; Knol AJ; Prinsen C; Boers JE
    Eur J Cancer; 2012 May; 48(7):1108-15. PubMed ID: 22446020
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Validation of Newly Developed Multiplex Kit Using Luminex xMAP Technology for Detecting Simultaneous RAS and BRAF Mutations in Colorectal Cancer: Results of the RASKET-B Study.
    Taniguchi H; Okamoto W; Muro K; Akagi K; Hara H; Nishina T; Kajiwara T; Denda T; Hironaka S; Kudo T; Satoh T; Yamanaka T; Abe Y; Fukushima Y; Yoshino T
    Neoplasia; 2018 Dec; 20(12):1219-1226. PubMed ID: 30412858
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Detection of
    Olmedillas-López S; Lévano-Linares DC; Alexandre CLA; Vega-Clemente L; Sánchez EL; Villagrasa A; Ruíz-Tovar J; García-Arranz M; García-Olmo D
    World J Gastroenterol; 2017 Oct; 23(39):7087-7097. PubMed ID: 29093617
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Evaluation of IntelliPlex™ KRAS G12/13 Mutation Kit for Detection of KRAS Mutations in Codon 12 and 13: A Novel Multiplex Approach.
    Chen CL; Chen CK; Ho CL; Chi WM; Yeh CH; Hu SP; Friebe P; Palmer S; Huang CS
    Mol Diagn Ther; 2019 Oct; 23(5):645-656. PubMed ID: 31347028
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cetuximab treatment for metastatic colorectal cancer with KRAS p.G13D mutations improves progression-free survival.
    Osumi H; Shinozaki E; Osako M; Kawazoe Y; Oba M; Misaka T; Goto T; Kamo H; Suenaga M; Kumekawa Y; Ogura M; Ozaka M; Matsusaka S; Chin K; Hatake K; Mizunuma N
    Mol Clin Oncol; 2015 Sep; 3(5):1053-1057. PubMed ID: 26623049
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Feasibility and robustness of amplification refractory mutation system (ARMS)-based KRAS testing using clinically available formalin-fixed, paraffin-embedded samples of colorectal cancers.
    Ogasawara N; Bando H; Kawamoto Y; Yoshino T; Tsuchihara K; Ohtsu A; Esumi H
    Jpn J Clin Oncol; 2011 Jan; 41(1):52-6. PubMed ID: 20696815
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Activating KRAS mutations and overexpression of epidermal growth factor receptor as independent predictors in metastatic colorectal cancer patients treated with cetuximab.
    Yen LC; Uen YH; Wu DC; Lu CY; Yu FJ; Wu IC; Lin SR; Wang JY
    Ann Surg; 2010 Feb; 251(2):254-60. PubMed ID: 20010090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan.
    Bibeau F; Lopez-Crapez E; Di Fiore F; Thezenas S; Ychou M; Blanchard F; Lamy A; Penault-Llorca F; Frébourg T; Michel P; Sabourin JC; Boissière-Michot F
    J Clin Oncol; 2009 Mar; 27(7):1122-9. PubMed ID: 19164213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.